On Friday, RBC Capital Markets adjusted its outlook on Bausch Health Companies (NYSE:BHC), raising the price target to $11 from the previous $10 while retaining a Sector Perform rating on the stock. The adjustment follows Bausch Health's third-quarter earnings report, which surpassed expectations with robust growth across all business segments.
Bausch Health reported third-quarter revenues of $2.51 billion, marking a 12% year-over-year increase and a 9% organic growth. These figures were approximately 5% higher than RBC Capital's estimates and 4% above the general market consensus. The company's strong quarter was partially attributed to certain one-time items that positively impacted the performance of RemainCo, which represents Bausch Health excluding Bausch + Lomb (BLCO).
The company's adjusted EBITDA for the quarter stood at $909 million, surpassing RBC Capital's estimates by roughly 9% and the consensus by about 8%. Bausch Health's management also highlighted their ongoing review of strategic options to maximize the value of BLCO's equity stake for the benefit of Bausch Health shareholders.
The increase in the price target to $11 is primarily due to revised assumptions about tax leakage in the event of a sale of BLCO, which RBC Capital now assumes has a 75% probability. The analyst's commentary indicated that these updated tax implications significantly influenced the new valuation.
In other recent news, Bausch Health Companies Inc. has reported a notable 7% year-over-year increase in revenues, marking its sixth consecutive quarter of revenue and adjusted EBITDA growth, excluding the Bausch + Lomb segment.
The company has also raised its full-year 2024 guidance, reflecting strong financial performance and confidence in its ongoing growth trajectory. Key contributors to this robust financial health include strong performances in the Salix and International segments and advances in strategic initiatives like the Red Sea program and AI-driven customer engagement.
In terms of future expectations, Bausch Health has raised its full-year 2024 revenue guidance to between $4.775 billion and $4.85 billion, with adjusted EBITDA expectations also increased to a range of $2.425 billion to $2.475 billion. The company's strategic priorities continue to focus on growth, innovation, and operational efficiency.
In other developments, the company has seen a 7% growth in the Salix segment, with XIFAXAN showing strong performance. The International segment experienced 8% organic growth, propelled by products like Contrave, and Solta Medical's organic growth was a remarkable 36%, with significant demand in South Korea and China. These are among the recent developments that underscore Bausch Health's resilience and strategic foresight in the competitive pharmaceutical landscape.
InvestingPro Insights
Bausch Health Companies' recent performance aligns with several key insights from InvestingPro. The company's strong quarterly revenue growth of 12.15% and a robust EBITDA growth of 8.18% over the last twelve months underscore the positive momentum highlighted in RBC Capital's report. These figures support the InvestingPro Tip that net income is expected to grow this year.
Additionally, the stock's significant return of 50.82% over the last three months reflects investor optimism, possibly fueled by the company's better-than-expected earnings. This aligns with another InvestingPro Tip noting a strong return over the last three months.
However, investors should be aware that the RSI suggests the stock is in overbought territory, which could indicate a potential for a short-term pullback. Despite this, analysts predict the company will be profitable this year, a positive sign for long-term investors.
For those seeking a more comprehensive analysis, InvestingPro offers 5 additional tips for Bausch Health Companies, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.